Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02TUL
|
|||
| Drug Name |
Ritlecitinib
|
|||
| Synonyms |
PF-06651600; CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
Click to Show/Hide
|
|||
| Indication | Alopecia areata [ICD-11: ED70.2] | Approved | [1] | |
| Alopecia [ICD-11: ED70; ICD-9: 704.09] | Phase 2/3 | [2] | ||
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 2 | [3] | ||
| Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 1 | [4] | ||
| Company |
Pfizer New York, NY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H19N5O
|
|||
| Canonical SMILES |
CC1CCC(CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
|
|||
| InChI |
1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
|
|||
| InChIKey |
CBRJPFGIXUFMTM-WDEREUQCSA-N
|
|||
| CAS Number |
CAS 1792180-81-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215830 | |||
| REF 2 | ClinicalTrials.gov (NCT03732807) PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.